BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 30865796)

  • 1. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
    Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
    J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
    Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
    J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
    Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
    N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Bempedoic Acid in Clinical Practice.
    Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
    Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
    JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.
    Cicero AFG; Fogacci F; Hernandez AV; Banach M;
    PLoS Med; 2020 Jul; 17(7):e1003121. PubMed ID: 32673317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS; Sulaica EM; Beavers CJ
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Goldberg AC; Banach M; Catapano AL; Duell PB; Leiter LA; Hanselman JC; Lei L; Mancini GBJ
    Atherosclerosis; 2023 Nov; 384():117192. PubMed ID: 37648637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).
    Ballantyne CM; Banach M; Bays HE; Catapano AL; Laufs U; Stroes ESG; Robinson P; Lei L; Ray KK
    Am J Cardiol; 2022 Jul; 174():1-11. PubMed ID: 35483979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
    Bilen O; Ballantyne CM
    Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
    Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
    Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
    Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
    J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.